5% leap in EU's R&D spending

15 October 2006

The 2006 European Union Industrial R&D Investment Scoreboard shows that the top 1,000 EU companies increased their R&D an average of 5.3 % in 2005. This figure is in line with the results of a European Commission survey released earlier this year. The top 1,000 non-EU companies raised their R&D investment 7.7%, showing a worldwide boost in R&D spending.

The EU maintains a high profile, with 18 of the top 50 R&D spenders and five of the 10 worldwide companies with the fastest R&D growth. These figures emerge from the analysis of the top 1,000 EU and 1,000 non-EU companies investing in R&D. The full report, including detailed sector-by-sector analysis will be available later this year.

After a period of sluggish R&D growth, this year's scoreboard shows a strong increase in R&D investment worldwide. An average growth rate for EU firms of 5.3% contrasts with last year's growth rate of 0.7% and a contraction of 2% in 2004. The R&D investment growth of companies in the rest of the world in 2005 was 7.7%, one percent higher than the previous year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight